Home
HelpTest Code CARTA Carbamazepine, Total, Serum
Reporting Name
Carbamazepine, Tot, SUseful For
Monitoring therapy
Determining compliance
Assessing toxicity
Method Name
Homogeneous Microparticle Agglutination Immunoassay
Performing Laboratory
Mayo Clinic Laboratories in Rochester
Specimen Type
Serum RedOrdering Guidance
This test measures carbamazepine only. For assessment of its active metabolite, carbamazepine-10,11-epoxide, which is the predominant form in children, order CARBG / Carbamazepine-10,11-Epoxide, Serum)
Specimen Required
Collection Container/Tube: Red top
Specimen Volume: 0.5 mL
Submission Container/Tube: Plastic vial
Collection Instructions: Centrifuge and aliquot serum into a plastic vial within 2 hours of collection.
Specimen Minimum Volume
0.25 mL
Specimen Stability Information
| Specimen Type | Temperature | Time | Special Container |
|---|---|---|---|
| Serum Red | Refrigerated (preferred) | 7 days | |
| Frozen | 28 days | ||
| Ambient | 48 hours |
Reject Due To
| Gross hemolysis | Reject |
Reference Values
Therapeutic: 4.0-12.0 mcg/mL
Critical value: ≥15.0 mcg/mL
Day(s) Performed
Monday through Sunday
CPT Code Information
80156
LOINC Code Information
| Test ID | Test Order Name | Order LOINC Value |
|---|---|---|
| CARTA | Carbamazepine, Tot, S | 3432-2 |
| Result ID | Test Result Name | Result LOINC Value |
|---|---|---|
| CARTA | Carbamazepine, Tot, S | 3432-2 |
Clinical Information
Carbamazepine (Tegretol) is used in the control of partial seizures with both temporal lobe and psychomotor symptoms as well as for generalized tonic-clonic seizures. It is also used for analgesia in trigeminal neuralgia.
Carbamazepine exhibits a volume of distribution of 1.4 L/kg with an elimination half-life of 15 hours. Protein binding averages 70%.
Carbamazepine-10,11-epoxide (CBZ10-11) is an active metabolite that represents the predominant form of the drug in children. The volume of distribution of CBZ10-11 is 1.1 L/kg, and the half-life is 5 to 8 hours.
Aplastic anemia and agranulocytosis are rare side effects of treatment with carbamazepine; baseline hematologic data should be documented before treatment is initiated.
Toxicity associated with carbamazepine overdose occurs when the blood level is 15.0 mcg/mL or higher and is typified by irregular breathing, muscle irritability, and hyperreflexia; followed by hyporeflexia, tachycardia, hypotension, and impaired consciousness with coma in severe toxicity. The higher the blood level, the more severe the symptoms.
Interpretation
Dosage adjustments are usually guided by monitoring blood levels. Most patients respond well when the serum concentration is in the range of 4.0 to 12.0 mcg/mL. Toxicity often occurs when levels are greater than or equal to 15.0 mcg/mL.
Cautions
Carbamazepine-10,11-epoxide (CBZ10-11) is not reported. A separate orderable test for this active metabolite is available (CARBG / Carbamazepine-10,11-Epoxide, Serum). Optimal response occurs when the CBZ10-11 serum level is in the range of 0.4 to 4.0 mcg/mL.
Clinical Reference
1. Cereghino JJ, Meter JC, Brock JT, Penry JK, Smith LD, White BG: Preliminary observations of serum carbamazepine concentration in epileptic patients. Neurology. 1973 Apr;23(4):357-366. doi: 10.1212/wnl.23.4.357
2. Patsalos PN, Berry DJ, Bourgeois BF, et al: Antiepileptic drugs--best practice guidelines for therapeutic drug monitoring: a position paper by the subcommission on therapeutic drug monitoring, ILAE Commission on Therapeutic Strategies. Epilepsia. 2008 Jul;49(7):1239-1276. doi: 10.1111/j.1528-1167.2008.01561.x
3. Scheuer ML, Pedley TA: The evaluation and treatment of seizures. N Engl J Med. 1990 Nov 22;323(21):1468-1474. 10.1056/NEJM199011223232107
4. Milone MC, Shaw LM: Therapeutic Drug Monitoring. In: Rifai N, Horvath AR, Wittwer CT, eds. Tietz Fundamentals of Clinical Chemistry and Molecular Diagnostics. 8th ed. Saunders; 2019:549
5. Patsalos PN, Zugman M, Lake C, James A, Ratnaraj N, Sander JW. Serum protein binding of 25 antiepileptic drugs in a routine clinical setting: a comparison of free non-protein-bound concentrations. Epilepsia. 2017 Jul;58(7):1234-1243. doi: 10.1111/epi.13802
Method Description
The ONLINE TDM Carbamazepine Gen.4 assay is a homogeneous microparticle agglutination immunoassay. It is a 2-reagent system used for the detection of carbamazepine in serum. Kinetic interaction of microparticles will be measured using automated analyzers. In this technology biotinylated drug hapten attached to streptavidin coated latex beads serves as the binding partner to anti-carbamazepine antibody. A competitive reaction to a limited amount of specific anti-carbamazepine antibody takes place between the latex bound hapten and free carbamazepine in the serum sample. A decrease in the apparent signal is proportional to the amount of drug present in the sample.(Package insert: ONLINE TDM Carbamazepine Gen.4. Roche Diagnostics; 04/2016)
Report Available
Same day/1 daySpecimen Retention Time
7 daysTest Classification
This test has been cleared, approved, or is exempt by the US Food and Drug Administration and is used per manufacturer's instructions. Performance characteristics were verified by Mayo Clinic in a manner consistent with CLIA requirements.Forms
If not ordering electronically, complete, print, and send 1 of the following forms with the specimen:
-Neurology Specialty Testing Client Test Request (T732)
-Therapeutics Test Request (T831)